Curiteva Welcomes David Schmidt As New Chief Commercial Officer To Boost Patient Care Innovations

Curiteva, a Huntsville, Alabama-based technology and manufacturing firm, recently announced a strategic enhancement to its executive leadership team with the appointment of David Schmidt as Chief Commercial Officer. This move signifies a pivotal step in Curiteva's ongoing commitment to pioneering advancements in patient care through innovative technology. Schmidt, with an illustrious career that spans over two decades in the medical device industry, is set to bring a wealth of experience and a robust track record of commercial success to the company.

David Schmidt's professional journey is marked by significant achievements and contributions to the medical device sector. He initiated his career with a groundbreaking startup, where he was instrumental in introducing one of the first interbody fusion implants, setting a new standard in spinal treatment. His career trajectory includes a successful stint as a spine implant distributor followed by a noteworthy 20-year tenure at Medtronic. At Medtronic, Schmidt held key leadership roles, managing enabling technology sales across the eastern half of the U.S. His tenure at Wright Medical further underscored his ability to drive sales, this time in the foot and ankle market. Prior to joining Curiteva, Schmidt was at the forefront of sales and marketing for a small spine company, showcasing his ability to lead and innovate.

Chad Falciani, Chair of the Board at Curiteva, expressed his enthusiasm for Schmidt's appointment, highlighting his exceptional leadership skills and proven sales expertise. Falciani is confident that Schmidt's experience with disruptive technologies and professional sales methods will align seamlessly with Curiteva's vision for the future.

Expressing his eagerness to contribute to Curiteva's mission, David Schmidt remarked on the company's commitment to innovation and leadership in transforming patient care. He noted his excitement about Curiteva's Inspire Technology and its potential based on early clinical data. Schmidt is keen on utilizing his extensive experience in commercial strategy to amplify Curiteva’s impact within the healthcare landscape.

About Curiteva:

Curiteva stands at the forefront of technological innovation in healthcare, specializing in the manufacturing of 3D printed Trabecular PEEK implants featuring a bioactive nano-surface. This cutting-edge approach is designed to revolutionize engineered structures and implant biomaterials by accelerating immunomodulation, enhancing healing processes, and ultimately improving patient outcomes. Founded on principles of world-class manufacturing, accelerated research and development, lean operational discipline, and delivering novel technology, Curiteva is dedicated to meeting the evolving needs of its customers and the patients they serve. For more information about Curiteva and its innovative solutions, visit their website at www.curiteva.com.